The estimated Net Worth of Martin I Freed is at least 430 千$ dollars as of 3 June 2021. Martin Freed owns over 3,333 units of Dicerna Pharmaceuticals Inc stock worth over 127,387$ and over the last 8 years he sold DRNA stock worth over 0$. In addition, he makes 302,750$ as Independent Director at Dicerna Pharmaceuticals Inc.
Martin has made over 1 trades of the Dicerna Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 3,333 units of DRNA stock worth 127,387$ on 3 June 2021.
The largest trade he's ever made was exercising 3,333 units of Dicerna Pharmaceuticals Inc stock on 3 June 2021 worth over 127,387$. On average, Martin trades about 185 units every 0 days since 2016. As of 3 June 2021 he still owns at least 3,333 units of Dicerna Pharmaceuticals Inc stock.
You can see the complete history of Martin Freed stock trades at the bottom of the page.
Dr. Martin I. Freed serves as Independent Director of the Company. Dr. Freed has served as an independent consultant to several private pharmaceutical, biotechnology, and healthcare companies, specializing in clinical and general pharmaceutical development and clinical and regulatory strategy since February 2015. He co-founded and served as Chief Medical Officer of Civitas Therapeutics, Inc., from December 2010 to October 2014 (acquired by Acorda Therapeutics, Inc. (“Acorda”)), and as Senior Vice President, Clinical Development of Acorda from October 2014 through January 2015. In addition, Dr. Freed has served as Chief Medical Officer and has provided strategic and operational planning and execution, as well as medical leadership for clinical pharmacology and development strategy and preclinical development for multiple pharmaceutical companies throughout his career. These companies include Avila Therapeutics, Inc., Taligen Therapeutics, Adnexus Therapeutics, Inc. (acquired by Bristol-Myers Squibb), and Vitae Pharmaceuticals, Inc. Dr. Freed spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals, where he served numerous roles including Vice President, Clinical Development and Medical Affairs in the metabolism therapeutic area. Dr. Freed currently serves as an independent director for Solid Biosciences Inc. and Sojournix, Inc., and previously served as an independent director of InteKrin Therapeutics Inc. from 2007 to 2010. He has authored over 100 publications or presentations. Dr. Freed has been Board Certified in Internal Medicine, Nephrology and Clinical Pharmacology. He performed his internal medicine residency at Temple University Hospital and nephrology fellowship at Yale-New Haven Hospital. A Fellow of the American College of Physicians, Dr. Freed received his B.S. with distinction in Biology from the University of Delaware and M.D. from Pennsylvania State University’s College of Medicine.
As the Independent Director of Dicerna Pharmaceuticals Inc, the total compensation of Martin Freed at Dicerna Pharmaceuticals Inc is 302,750$. There are 9 executives at Dicerna Pharmaceuticals Inc getting paid more, with Douglas Fambrough having the highest compensation of 5,048,130$.
Martin Freed is 59, he's been the Independent Director of Dicerna Pharmaceuticals Inc since 2016. There are 4 older and 9 younger executives at Dicerna Pharmaceuticals Inc. The oldest executive at Dicerna Pharmaceuticals Inc is Patrick Gray, 71, who is the Independent Director.
Martin's mailing address filed with the SEC is C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN, MA, 02129.
Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over 233,644,011$ worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth 36,501,331$ . The most active insiders traders include Capital Management, Llc Kol...、Nicole Vitullo、Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of 4,025,674$. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth 78,351$.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include: